Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — Investor Presentation (August 2026)
29 slides from Oncoinvent Asa's investor presentation, August 2026
Slide 1: Oncoinvent: Transforming cancer care through direct alpha therapy
Oncoinvent Transforming cancer care through direct alpha therapy August 2026
Slide 2: Early signals of efficacy and safety, platform potential, experienced team
Early signals of efficacy and safety, platform potential across many high-unmet need indications, and an experienced team with a proven track record High unmet medical need from cancers in the peritoneum • • No approved drugs or product aimed specifically at prevention of local peritoneal disease
Slide 3: Radiopharmaceutical excellence: expertise across the spectrum
Radiopharmaceutical excellence: expertise across the spectrum Scientific founders Roy Larsen Øyvind Bruland Team Oystein Soug Gro Hjellum Ramzi Amri Kari Myren Anne-Kirsti Aksnes Kristine Lofthus Sara Westrøm Chief Executive Officer Chief Operations Officer Chief Financial Officer Chief Medical Offi
Slide 4: Peritoneal metastases - urgent need for novel treatments
Peritoneal metastases - urgent need for novel treatments • Peritoneal metastases arise from many different primary cancers • The only treatment option with curative intent is surgery, effect of systemic therapy limited • Surgery leaves behind micro-metastases giving rise to new metastases and diseas
Slide 5: In ovarian cancer, spread to the peritoneum is the norm, so is recurrence
In ovarian cancer, spread to the peritoneum is the norm, so is recurrence, with high mortality as a consequence 70% of OC patients have peritoneal Up to 85% relapse post resection Relapsed OC is largely incurable, micrometastases (PM) at diagnosis median survival is ~6-36 months • Most OC patients p
Slide 6: Radspherin - alpha therapy targeted to and retained in the peritoneum
Radspherin® - alpha therapy targeted to and retained in the peritoneum Radspherin® • Combining alpha-emitting 224Ra with CaCO3 microparticles • Half-life 3.6 days • Therapy with depot effect - 75% of radiation dose delivered the first week • Shelf life 8 days allowing for centralized manufacturing •
Slide 7: Radspherin - alpha therapy targeted to and retained in the peritoneum
Radspherin® - alpha therapy targeted to and retained in the peritoneum Radspherin® How does it work? • Combining alpha-emitting 224Ra with • Delivering a high dose of alpha-radiation CaCO3 microparticles directly to the peritoneum through an in- dwelling catheter • Half-life 3.6 days • Administratio
Slide 8: Our current focus is on Ovarian Cancer, with pipeline opportunities
Our current focus is on Ovarian Cancer, with pipeline opportunities leveraging the same drug in CRC and several other malignancies 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 RAD-18-001 Ovarian, recurrent phase 1 Platinum-sensitive recurrent patients after secondary debulking RAD-18-002 Colorectal phase
Slide 9: Radspherin value proposition: a solution for a broad population with high unmet need
Radspherin® value proposition lies in providing a solution for a broad population with high unmet need Radspherin demonstrates meaningful potential, supported by its favorable efficacy and safety profile, single-dose administration, and focus on a population with substantial unmet need search 2025 R
Slide 10: Radspherin fills a unique pocket of value with high barriers to entry
Radspherin® fills a unique pocket of value in a high-demand area with equally high barriers to entry Procedure-based Biologics / SoC Radiopharmaceuticals locoregional chemo immunotherapies Farletuzumab Radspherin® KORJUNY® IMNN-001 Systemic chemo XLNT-1 HIPEC PIPAC ²¹¹At- Development stage ● ● ● ● ●
Slide 11: Radiopharma landscape: Oncoinvent pursues peritoneal metastases
While the radiopharma sector is largely concentrated in two indications, Oncoinvent pursues peritoneal metastases Snapshot of the Radiopharma Landscape 224Ra 212Pb 225Ac 177Lu Other Commentary metastases Peritoneal • Harnessing the advantages of radiopharmaceuticals with reduced complexity and risk
Slide 12: Radspherin in ovarian cancer alone has blockbuster potential in US+EU5
Radspherin® in ovarian cancer alone has blockbuster potential in US+EU5 Incidence PM rate Eligible Addressable Treated at Price per Total peak sales peak treatment US + EU5, base case6 US list; EU5 at 40% of US6 ~57k ~40k ~32k ~24k ~8.4k US ~25k EU5 ~32k ~70% has Peritoneal Metastases at first-line
Slide 13: Radspherin in colorectal cancer PM adds ~$640m peak potential
Radspherin® in colorectal cancer PM adds ~$640m peak potential in US+EU5 Incidence PM rate Eligible Addressable Treated at Peak sales Total peak sales peak split US + EU5, base case4 ~505k ~30k ~14k ~12.5k ~4.8k US ~195k EU5 ~310k ~6% Synchronous PM2 40% US · 50% EU5 Cytoreduction4 ~90% Complete res
Slide 14: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 RAD-18-001 Ovarian, recurrent phase 1 Platinum-sensitive recurrent patients after secondary debulking RAD-18-002 Colorectal phase 1/2a Primary and recurrent, after cytoreductive surgery and HIPEC* RAD-18-003 Ovarian, primary phase
Slide 15: Radspherin - phase 1 study in ovarian cancer
Radspherin® - phase 1 study in ovarian cancer RAD-18-001: in patients after secondary debulking 4 clinical sites: surgery of platinum-sensitive recurrent ovarian cancer • Oslo, Norway(PI: Yun Wang) • single-arm open label study • Leuven, Belgium (PI: Els van Nieuwenhuysen) • 3 + 3 dose-escalation (1
Slide 16: Ovarian Phase 1: recurrence was rarely peritoneal at 24 months
Ovarian Phase 1: recurrence was rarely peritoneal at 24 months Final 24-month follow-up | 10 patients at the recommended 7 MBq dose Overall recurrence rate 10% Radspherin® (RAD-18-001, n=10) 30% peritoneal recurrence Historical benchmark* 1 of 10 patients at 24 months ~55–60% + two lymph-node recurr
Slide 17: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 RAD-18-001 Ovarian, recurrent phase 1 Platinum-sensitive recurrent patients after secondary debulking RAD-18-002 Colorectal phase 1/2a Primary and recurrent, after cytoreductive surgery and HIPEC* RAD-18-003 Ovarian, primary phase
Slide 18: Design: Phase 1/2a in colorectal cancer
Design: Phase 1/2a in colorectal cancer The trial: (RAD-18-002) Radspherin after Two clinical sites: cytoreductive surgery and HIPEC in patients with peritoneal metastasis from colorectal cancer • Oslo, Norway (PI: Stein Larsen) • Uppsala, Sweden (PI: Wilhelm Graf) • Single-arm open label study • 3
Slide 19: Colorectal Phase 1/2a: the same compartment-level signal, a second tumor
Colorectal Phase 1/2a: the same compartment-level signal, a second tumor Final 18-month follow-up | 36 patients at the recommended 7 MBq dose Peritoneal recurrence rate · Radspherin® vs a literature benchmark (same endpoint) Radspherin® (n=36, 7 MBq) Literature benchmark* 28% peritoneal recurrence ~
Slide 20: Controlling peritoneal disease may significantly improve survival in colorectal cancer
Controlling peritoneal disease may significantly improve survival in colorectal cancer First disease recurrence after treatment 1 Impact of site of first site of recurrence 1 1/3 peritoneal only Median overall survival - from the time of recurrence: 1/3 combined • After distant metastasis only: 44 m
Slide 21: Radspherin has an inherent edge in its safety profile
Through its design, Radspherin® has an inherent edge in its safety profile through its self-contained nature within the peritoneal cavity • Ovarian Phase 1 (n=21) and colorectal Phase 1/2a (n=47) No dose-limiting toxicity across 68 patients • No increase in event rates with increasing dose levels Ad
Slide 22: Our current focus is on Ovarian Cancer, with pipeline opportunities
Our current focus is on Ovarian Cancer, with pipeline opportunities leveraging the same drug in CRC and several other malignancies 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 RAD-18-001 Ovarian, recurrent phase 1 Platinum-sensitive recurrent patients after secondary debulking RAD-18-002 Colorectal phase
Slide 23: Randomized Phase 2 study in first-line treatment of ovarian cancer
Randomized Phase 2 study in first-line treatment of ovarian cancer Patient population • primary advanced ovarian cancer Randomised SoC+ Radspherin Primary • undergoing neoadjuvant Safety Imaging every cohort endpoint: chemotherapy and interval run-in 2:1 3 months up ~110 ITT progression- debulking s
Slide 24: PFS is a credible read on overall survival
PFS is a credible read on overall survival • Recognized by the Gynecologic Cancer InterGroup and by regulators as a An accepted 1 regulatory endpoint valid primary endpoint for first-line ovarian cancer trials • Basis on which recent first-line agents were approved • At the patient level, progressio
Slide 25: One product, many tumors: the mechanism ignores the target
One product, many tumors: the mechanism ignores the target Receptor-independent, addressable across any cancer that seeds the peritoneum: Targeted therapy Compartment Needs therapy: molecular target Radspherin® Secondary extraperitoneal Secondary intraperitoneal on the tumor Needs only origin origin
Slide 26: Targeting by proximity – brilliant in its simplicity
Targeting by proximity – brilliant in its simplicity Bypasses Retains Increases the need of the radioactive the radionuclide biological targeting payload in the exposure at the and systemic target area tumor target sites distribution of the radioactive payload Reduces the radionuclide exposure to ra
Slide 27: In-house GMP pilot plant with attractive capabilities
In-house GMP pilot plant with attractive capabilities Oncoinvent has in-house GMP 224Ra produced from 228Th, which Microparticles and finished goods production capability has multiple sources produced in-house • Capacity of ~200 doses Radspherin annually, outsourcing and scale-up required for phase
Slide 28: Radspherin - solid multilayer intellectual property protection
Radspherin® - solid multilayer intellectual property protection Radspherin® composition of matter & use • Granted in US, EU, China, Japan and additional countries • Patent expiry 2035 (2036 in some countries) with an option for 5 years extension Radspherin® formulation • Granted in China • Filed in
Slide 29: Early signals of efficacy and safety, platform potential, experienced team
Early signals of efficacy and safety, platform potential across many high-unmet need indications, and an experienced team with a proven track record High unmet medical need from cancers in the peritoneum • • No approved drugs or product aimed specifically at prevention of local peritoneal disease